systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-276Research ArticleСТАТЬИARTICLES«Ингибиторы ангиотензинпревращающего фермента или сартаны у больных с высоким риском развития осложнений сердечно-сосудистых заболеваний» – неправильный вопрос или нежелательный ответAngiotensin-converting enzyme inhibitors or sartans in patients at high risk for cardiovascular events: a wrong question or an undesirable answerГиляревскийС. Р.GilyarevskyS. R.noemail@neicon.ruОрловВ. А.OrlovV. A.noemail@neicon.ruКузьминаИ. М.KuzminaI. M.noemail@neicon.ruГолшмидМ. В.GolshmidM. V.noemail@neicon.ruГБОУ ДПО Российская медицинская академия последипломного образования Минздрава РФRussian FederationМосковский городский научно-исследовательский институт скорой помощи им. Н.В.СклифосовскогоRussian Federation2013231220221013538Copyright © Гиляревский С.Р., Орлов В.А., Кузьмина И.М., Голшмид М.В., 20222022Гиляревский С.Р., Орлов В.А., Кузьмина И.М., Голшмид М.В.Gilyarevsky S.R., Orlov V.A., Kuzmina I.M., Golshmid M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/276

В статье обсуждаются современные представления о роли применения ингибиторов ангиотензинпревращающего фермента и блокаторов рецепторов ангиотензина II с целью профилактики развития тяжелых осложнений сердечно-сосудистых заболеваний. Приводятся как соответствующие доказательные данные, так и мнения экспертов. Рассматриваются возможные причины клинической инертности, обусловливающей отклонения в тактике применения средств, подавляющих активность ренин-ангиотензиновой системы.

The paper discusses current views on the role of using angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers to prevent severe cardiovascular events. It gives both respective documentary information and experts’ opinions. The possible causes of clinical inertness defining deviations in the tactics of using drugs that suppress the activity of the renin-angiotensin system are considered.

ингибиторы ангиотензинпревращающего ферментаблокаторы рецепторов ангиотензина IIклиническая инертностьangiotensin-converting enzyme inhibitorsangiotensin II receptor blockersclinical inertnessReferencesHeart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin - converting - enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145–53 [Errata, N Engl J Med 2000; 342: 784, 1376].Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin - converting - enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145–53 [Errata, N Engl J Med 2000; 342: 784, 1376].Fox K.M. European trial On reduction of cardiac events with Perindopril instable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double - blind, placebo - controlled, multicentretrial (the EUROPA study). Lancet 2003; 362: 782–8.Fox K.M. European trial On reduction of cardiac events with Perindopril instable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double - blind, placebo - controlled, multicentretrial (the EUROPA study). Lancet 2003; 362: 782–8.Nissen S.E., Tuzcu E.M., Libby P. et al. Effectof antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure.JAMA 2004; 292: 2217–26.Nissen S.E., Tuzcu E.M., Libby P. et al. Effectof antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure.JAMA 2004; 292: 2217–26.Braunwald E, Domanski M.J., Fowler S.E. et al. Angiotensin - converting - enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058–68.Braunwald E, Domanski M.J., Fowler S.E. et al. Angiotensin - converting - enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058–68.Phillips L.S., Branch W.T., Cook C.B. et al. Clinicalinertia. Ann Intern Med 2001; 135: 825–34.Phillips L.S., Branch W.T., Cook C.B. et al. Clinicalinertia. Ann Intern Med 2001; 135: 825–34.Giugliano D, Esposito K. Clinical inertiaas a clinical safeguard.JAMA 2011; 305: 1591–2.Giugliano D, Esposito K. Clinical inertiaas a clinical safeguard.JAMA 2011; 305: 1591–2.Avignon A, Attali C, Sultan A et al. Clinical inertia: view points of general practitioners and diabetologists. Diabetes Metab 2012; 38 (Suppl. 3): S53–S58.Avignon A, Attali C, Sultan A et al. Clinical inertia: view points of general practitioners and diabetologists. Diabetes Metab 2012; 38 (Suppl. 3): S53–S58.Cowart J.B., Taylor A.A. Should two - drug initial therapy for hypertension be recommended forallpatients? Curr Hypertens Rep 2012; 14: 324–32.Cowart J.B., Taylor A.A. Should two - drug initial therapy for hypertension be recommended forallpatients? Curr Hypertens Rep 2012; 14: 324–32.Pateland J.A., Fotis M.A. Comparison of Treatment of Patients With Congestive Heart Failure by Cardiologists Versus Noncardiologists. Am J Health Syst Pharm 2005; 62: 168–72.Pateland J.A., Fotis M.A. Comparison of Treatment of Patients With Congestive Heart Failure by Cardiologists Versus Noncardiologists. Am J Health Syst Pharm 2005; 62: 168–72.Lichter A.S., McKinney R. Toward a harmonized and centralized conflict finterest disclosure: progress froman IOM initiative.JAMA 2012; 308: 2093–4.Lichter A.S., McKinney R. Toward a harmonized and centralized conflict finterest disclosure: progress froman IOM initiative.JAMA 2012; 308: 2093–4.Choudhry N.K., Fletcher R.H., Soumerai S.B. Systematicreview: the relationship between clinical experience and quality of healthcare. Ann Intern Med 2005; 142: 260–73.Choudhry N.K., Fletcher R.H., Soumerai S.B. Systematicreview: the relationship between clinical experience and quality of healthcare. Ann Intern Med 2005; 142: 260–73.Gerstein H.C., Bosch J, Dagenais G.R. et al. ORIGIN Trial Investigators. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia 2012; 367: 319–28.Gerstein H.C., Bosch J, Dagenais G.R. et al. ORIGIN Trial Investigators. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia 2012; 367: 319–28.Rizos E.C., Ntzani E.E., Bika E. et al. Associationbetween omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta - analysis.JAMA 2012; 308: 1024–33.Rizos E.C., Ntzani E.E., Bika E. et al. Associationbetween omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta - analysis.JAMA 2012; 308: 1024–33.The ONTARGET Investigators. Telmisartan, Ramipril, or Bothin Patientsat High Risk for Vascular Events. N Engl J Med 2008; 358: 1547–59.The ONTARGET Investigators. Telmisartan, Ramipril, or Bothin Patientsat High Risk for Vascular Events. N Engl J Med 2008; 358: 1547–59.Piaggio G, Elbourne D.R., Pocock S.J. et al. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement.JAMA 2012; 308: 2594–604.Piaggio G, Elbourne D.R., Pocock S.J. et al. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement.JAMA 2012; 308: 2594–604.Savarese G, Costanzo P, Cleland J.G. et al. A meta - analysis reporting effects of angiotensin - converting enzyme inhibitors and angiotensin receptor blockers in patients with outheart failure. J Am Coll Cardiol 2013; 61: 131–42.Savarese G, Costanzo P, Cleland J.G. et al. A meta - analysis reporting effects of angiotensin - converting enzyme inhibitors and angiotensin receptor blockers in patients with outheart failure. J Am Coll Cardiol 2013; 61: 131–42.Moher D, Liberati A, Tetzlaff J, Altman D.G. PRISMA Group. Prefer redreporting items for systematic reviews and meta - analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006–12.Moher D, Liberati A, Tetzlaff J, Altman D.G. PRISMA Group. Prefer redreporting items for systematic reviews and meta - analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006–12.Van Vark L.C., Bertrand M, Akkerhuis K.M. et al. Angiotensin - converting enzyme inhibitors reduce mortality in hypertension: a meta - analysis of randomized clinical trials of renin - angiotensin - aldosterone system inhibitors in volving 158,998 patients. Eur Heart J 2012; 33: 2088–97.Van Vark L.C., Bertrand M, Akkerhuis K.M. et al. Angiotensin - converting enzyme inhibitors reduce mortality in hypertension: a meta - analysis of randomized clinical trials of renin - angiotensin - aldosterone system inhibitors in volving 158,998 patients. Eur Heart J 2012; 33: 2088–97.

The authors declare that there are no conflicts of interest present.